LJAC
ELVN icon

L.J. Altfest & Co’s Enliven Therapeutics ELVN Stock Holding History

L.J. Altfest & Co’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,809
Closed -$120K – 260
2021
Q2 		$120K Buy
3,809
+74
+2% +$2.29K 0.03% 261
2021
Q1 		$126K Buy
+3,735
New +$190K 0.03% 268

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

L.J. Altfest & Co's ELVN Position: Q3 2021 in Review

L.J. Altfest & Co sold out of Enliven Therapeutics (ELVN) in Q3 2021, closing a stake of 3,809 shares — an estimated $120K sold.

L.J. Altfest & Co first reported a position in ELVN in Q1 2021 and held it in 2 quarters. The position peaked at $126K in Q1 2021. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2021.

  • L.J. Altfest & Co reported no remaining Enliven Therapeutics position as of Q3 2021 after selling out during the quarter.
  • L.J. Altfest & Co sold 3,809 Enliven Therapeutics shares in Q3 2021, an estimated $120K.
  • L.J. Altfest & Co first reported a position in Enliven Therapeutics in Q1 2021 and held it in 2 quarters.
  • L.J. Altfest & Co's Enliven Therapeutics position peaked at $126K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2021.

Based on L.J. Altfest & Co's 13F filing for Q3 2021, filed 12 Oct 2021.